| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Beijing Science Sun Pharmaceutical Co., Ltd. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | CN¥7.65 |
| 52 Week High | CN¥12.27 |
| 52 Week Low | CN¥6.53 |
| Beta | 0.015 |
| 1 Month Change | -10.21% |
| 3 Month Change | 11.03% |
| 1 Year Change | -29.95% |
| 3 Year Change | -36.36% |
| 5 Year Change | -28.30% |
| Change since IPO | -44.75% |
Recent News & Updates
Shareholder Returns
| 300485 | CN Biotechs | CN Market | |
|---|---|---|---|
| 7D | 6.8% | 2.6% | 1.2% |
| 1Y | -29.9% | -19.6% | -12.6% |
Return vs Industry: 300485 underperformed the CN Biotechs industry which returned -19.6% over the past year.
Return vs Market: 300485 underperformed the CN Market which returned -12.6% over the past year.
Price Volatility
| 300485 volatility | |
|---|---|
| 300485 Average Weekly Movement | 7.1% |
| Biotechs Industry Average Movement | 7.7% |
| Market Average Movement | 8.3% |
| 10% most volatile stocks in CN Market | 12.1% |
| 10% least volatile stocks in CN Market | 5.0% |
Stable Share Price: 300485 has not had significant price volatility in the past 3 months.
Volatility Over Time: 300485's weekly volatility (7%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1999 | 532 | Biao Ma | www.ssyy.com.cn |
Beijing Science Sun Pharmaceutical Co., Ltd. engages in the research and development, production, and sales of injections in China. It offers products for cardiovascular, cerebrovascular, immunomodulation, nervous systems, and other varieties.
Beijing Science Sun Pharmaceutical Co., Ltd. Fundamentals Summary
| 300485 fundamental statistics | |
|---|---|
| Market cap | CN¥3.68b |
| Earnings (TTM) | -CN¥88.52m |
| Revenue (TTM) | CN¥453.41m |
8.1x
P/S Ratio-41.6x
P/E RatioIs 300485 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 300485 income statement (TTM) | |
|---|---|
| Revenue | CN¥453.41m |
| Cost of Revenue | CN¥140.03m |
| Gross Profit | CN¥313.38m |
| Other Expenses | CN¥401.91m |
| Earnings | -CN¥88.52m |
Last Reported Earnings
Mar 31, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.18 |
| Gross Margin | 69.12% |
| Net Profit Margin | -19.52% |
| Debt/Equity Ratio | 0% |
How did 300485 perform over the long term?
See historical performance and comparison